TY - JOUR
T1 - Trial Watch
T2 - Immunostimulation with recombinant cytokines for cancer therapy
AU - García-Martínez, Elena
AU - Smith, Melody
AU - Buqué, Aitziber
AU - Aranda, Fernando
AU - Peña, Francisco Ayala de la
AU - Ivars, Alejandra
AU - Cánovas, Manuel Sanchez
AU - Conesa, Ma Angeles Vicente
AU - Fucikova, Jitka
AU - Spisek, Radek
AU - Zitvogel, Laurence
AU - Kroemer, Guido
AU - Galluzzi, Lorenzo
N1 - Publisher Copyright:
© 2018 Taylor & Francis Group, LLC.
PY - 2018/6/3
Y1 - 2018/6/3
N2 - Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-α2a and IFN-α2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-α2a and IFN-α2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, research in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize research preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients.
AB - Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-α2a and IFN-α2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-α2a and IFN-α2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, research in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize research preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients.
KW - CAR T cells
KW - CTLA4
KW - GM-CSF
KW - IL-15
KW - PD-1
KW - pembrolizumab
UR - http://www.scopus.com/inward/record.url?scp=85046862171&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2018.1433982
DO - 10.1080/2162402X.2018.1433982
M3 - Review article
C2 - 29872569
AN - SCOPUS:85046862171
SN - 2162-4011
VL - 7
JO - OncoImmunology
JF - OncoImmunology
IS - 6
M1 - e1433982
ER -